Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Other news to note for Nov. 20, 2020

Proscia
By Author Proscia | November 22, 2020

Proscia Inc., a Philadelphia-based provider of digital and computational pathology solutions, said that NASA’s Jet Propulsion Laboratory and the National Cancer Institute Consortium for Molecular Characterization of Screen-Detected Lesions, coordinated by Baylor College of Medicine, have deployed Proscia’s Concentriq platform to advance biomedical research on improving cancer treatment.

Our website uses cookies. By using this site, you agree to its use of cookies.